Research programme: pain therapy - Penwest/Laboratoires IrexAlternative Names: Pain therapy research programme - Penwest/Laboratoires Irex
Latest Information Update: 23 Jan 2004
At a glance
- Originator Laboratoires Irex; Penwest Pharmaceuticals
- Developer Penwest Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 23 Jan 2004 Discontinued - Preclinical for Pain in USA (unspecified route)
- 12 Jul 2001 Preclinical development for Pain in USA (Unknown route)